Industry · AI News ·
Takeda signs US$600M AI drug discovery deal with Insilico
Takeda has signed a strategic collaboration with Insilico Medicine to use its AI platform for early-stage drug discovery across Takeda’s therapeutic areas. The companies did not disclose the specific disease targets or areas covered by the agreement.